CD25 EXPRESSION ON THE SURFACE OF JURKAT CELLSстатья

Информация о цитировании статьи получена из Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 21 августа 2017 г.

Работа с статьей


[1] Cd25 expression on the surface of jurkat cells / E. V. Mityushova, A. N. Shatrova, N. A. Aksenov, I. I. Marakhova // Cell and Tissue Biology. — 2015. — Vol. 9, no. 5. — P. 364–370. Expression of the αsubunit of the interleukin2 receptor (IL2Rα) was assessed by quantifying CD25 upregulation in the Jurkat cell line (human acute T cell leukemia). It was found that phytohemagglutinin (PHA, 5 μmL) or PHA in combination with 12,13phorbol dibutirate (PDBu, 10–8 M) increased the number of CD25positive cells in the proliferating Jurkat culture. In 24 h, their number was 32.3 ± 3.4 (n = 11) and 44.8 ± 8.6% (n = 6), respectively. Interleukin2 (IL2, 200 U/mL), alone or together with PDBu, did not induce CD25 expression in Jurkat cells. The agents regulating normal Tcell proliferation did not affect Jurkat cell growth. It was found that, unlike normal human blood lymphocytes, tyrphostin WHIP131, an inhibitor of JAK/STAT signaling from the IL2 receptor to CD25, inhibited Jurkat cell growth and blocked the cell cycle in G2/M rather than decreasing the induced CD25+ cell number. It has been concluded that transformed IL2independent Jurkat Tcells do not lose the mechanism of IL2Rα expression. WHIP131, an inhibitor of IL2 receptorassociated tyrosine kinase, JAK3 arrests the cell cycle at G2/M phase and has targets other than JAK3.

Публикация в формате сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл сохранить в файл скрыть